Table 2 Cox regression models on overall survival and progression-free survival

Sex (M vs F)

1.71 (0.96–3.05), P = 0.07

1.35 (0.82–2.21) P = 0.24

Age (years)

1.00 (0.98–1.02), P = 0.72

1.00 (0.98–1.01) P = 0.74

Lines of treatment:

P = 0.55

P = 0.63

 2 vs 1

1.23 (0.57–2.64)

1.06 (0.56–1.99)

  ≥ 3 vs 1

1.56 (0.69–3.55)

1.35 (0.67–2.73)

BRAF (mutant vs wild-type)

1.14 (0.64–2.04), P = 0.65

1.32 (0.80–2.19) P = 0.28

Brain metastases (yes vs no)

1.03 (0.56–1.87), P = 0.93

1.30 (0.77–2.18) P = 0.32

Lactate dehydrogenase (≥454 vs < 454)

3.06 (1.69–5.57), P < 0.0001

2.51 (1.36–4.64), P = 0.003

2.16 (1.18–3.99) P = 0.01

1.74 (1.03–2.94) P = 0.04

Absolute neutrophil count (≥5.4 vs < 5.4)

2.04 (1.17–3.57), P = 0.01

1.60 (0.98–2.61) P = 0.06

White blood cell count (≥7.6 vs < 7.6)

1.57 (0.91–2.73), P = 0.11

1.55 (0.95–2.54) P = 0.08

Neutrophil-to-lymphocyte ratio (≥5.0 vs < 5.0)

3.53 (2.02–6.16), P < 0.0001

2.85 (1.60–5.08), P < 0.0001

2.53 (1.53–4.18) P < 0.0001

2.10 (1.23–3.59) P = 0.007

Derived neutrophil-to-lymphocyte ratio (≥3.0 vs < 3.0)

2.70 (1.55–4.69), P < 0.0001

2.50 (1.48–4.23) P = 0.001